Analysts Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) PT at $23.43

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $23.43.

TEVA has been the topic of several research analyst reports. StockNews.com cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Thursday, March 27th. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Bank of America decreased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Finally, Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th.

Remove Ads

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently made changes to their positions in TEVA. Oarsman Capital Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $44,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $66,000. Finally, IFP Advisors Inc lifted its position in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Down 0.3 %

Shares of NYSE:TEVA traded down $0.05 during mid-day trading on Friday, hitting $15.25. The stock had a trading volume of 1,727,462 shares, compared to its average volume of 9,668,956. The company's 50 day moving average is $16.95 and its 200-day moving average is $18.08. Teva Pharmaceutical Industries has a 12-month low of $12.51 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a market cap of $17.29 billion, a PE ratio of -10.51, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.